About CytoSolv
CytoSolv is a company based in Newport (United States) founded in 2009 was acquired by Semma Therapeutics in November 2015. CytoSolv has raised $500 thousand across 5 funding rounds from investors including Semma Therapeutics, National Science Foundation and Slater Technology Fund. CytoSolv operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Cellino, among others.
- Headquarter Newport, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$500 K (USD)
in 5 rounds
-
Latest Funding Round
$150 K (USD), Grant
Jan 01, 2013
-
Investors
Semma Therapeutics
& 3 more
-
Employee Count
Not available
-
Acquired by
Semma Therapeutics
(Nov 16, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CytoSolv
CytoSolv has successfully raised a total of $500K across 5 strategic funding rounds. The most recent funding activity was a Grant round of $150 thousand completed in January 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CytoSolv
CytoSolv has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Semma Therapeutics, National Science Foundation and Slater Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC investments are directed toward US and UK companies.
|
Locked | Locked | Locked | |
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked | |
|
Develops cell therapy treatments for neurodegenerative diseases.
|
Locked | Locked | Locked |
Investor details for CytoSolv
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CytoSolv
Investment portfolio details for CytoSolv
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CytoSolv
Detailed financials for CytoSolv
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cytosolv Comparisons
Peer comparison for CytoSolv
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CytoSolv
CytoSolv operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Cellino, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Pendulum is focused on developing advanced probiotic solutions.
|
Detailed competitors of CytoSolv
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytosolv
Complete news archive for CytoSolv
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytoSolv
CytoSolv was founded in 2009 and raised its 1st funding round 1 year after it was founded.
CytoSolv is headquartered in Newport, United States. It is registered at Newport, Rhode Island, United States.
CytoSolv is a funded company, having raised a total of $500K across 5 funding rounds to date.
CytoSolv was founded in 2009 in Newport, United States, as a biotech firm focused on encapsulating cell technology within the cell therapy sector. Initial efforts targeted therapies for diabetic foot ulcer wound healing, with operations later shifted toward broader encapsulating applications. The company was acquired by Semma Therapeutics on November 16, 2015, concluding its independent development activities.
CytoSolv's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
CytoSolv has 4 investors. Key investors include Semma Therapeutics, National Science Foundation, Slater Technology Fund, and Living Cell Technologies.